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Summary
 
Background 
 
A defect in hypothalamic–pituitary–adrenal (HPA)
axis function has been suggested to contribute to susceptibility to
rheumatoid arthritis (RA).
 
Objective 
 
To  investigate polymorphisms of the glucocorticoid
receptor (GR) gene and determine any associations with RA.
 
Methods 
 
Three GR polymorphisms that tag 95% of all haplotypes
across the GR gene were genotyped. These are an intron B Bcl1
polymorphism, a ttg insertion/deletion within intron F (rs2307674)
and the single nucleotide polymorphism (SNP) lying in the 3
 
′
 
untranslated region of exon 9b (rs6198). The dye terminator-based
SNaPshot method or size resolution by capillary electrophoresis was
performed. The study population comprised 198 UK Caucasian RA
cases and 393 ethnically matched controls.
 
Results 
 
No signiﬁcant single point or haplotypic associations were
found for GR polymorphisms with RA susceptibility. Furthermore, no
evidence for GR polymorphisms with aspects of RA severity was seen.
 
Conclusion 
 
In this study of the most comprehensive coverage of
GR polymorphisms with RA, no signiﬁcant contributing role for GR
polymorphisms with RA was found.
(Received 25 January 2007; returned for revision 8 March 2007; 
 
ﬁnally revised 14 March 2007; accepted 15 March 2007)
 
Introduction
 
Studies from both animals and humans suggest that a defect in the
neuroendocrine system may be important in the disease rheumatoid
arthritis (RA). Inappropriately normal plasma cortisol and a blunted
response of plasma cortisol to surgical stress have been shown for
RA patients.
 
1,2
 
 Glucocorticoids (Gcs) are required for the development
of streptococcal cell wall-induced arthritis in Lewis rats.
 
3
 
 Further-
more, while many RA patients respond well to exogenous Gc
treatment, a proportion fail to do so.
 
4
 
 These observations suggest
that hypothalamic–pituitary–adrenal (HPA) axis dysregulation
or relative Gc deﬁciency contributes to the onset of RA.
Gcs exert their effect by binding to the intracellular receptor, the
glucocorticoid receptor alpha (GR
 
α
 
). The human GR gene (GCCR,
GCR, GRL, NR3C1) (locus 5q31) is 10 exons in length and exons
1–9
 
α
 
 are transcribed into GR
 
α
 
 mRNA, which is translated into
a functional receptor (GR
 
α
 
). Alternative splicing of the primary
transcript results in an mRNA containing exons 1–9
 
β
 
, which gives
rise to the GR
 
β
 
. Unlike GR
 
α
 
, GR
 
β
 
 does not bind hormone and is
transcriptionally inactive.
 
5,6
 
 Although a dominant negative effect
of GR
 
β
 
 on GR
 
α
 
 activity has been known for some time, the
mechanism by which this occurs is not known and the precise
functional signiﬁcance of GR
 
β
 
 remains unclear. Several associations
with GR
 
β
 
 overexpression and autoimmune/inﬂammatory diseases
have been described. It is not known, however, whether this is a cause
or consequence of the inﬂammatory state and whether the increase
in the GR
 
β
 
 is sufﬁcient to exert a dominant negative effect on GR
 
α
 
.
It has been suggested that GR
 
β
 
 could in part mediate Gc resistance
seen in RA.
 
7
 
Derijk 
 
et al
 
. described an A to G polymorphism at position 3736 in
exon 9b (now rs6198).
 
8
 
 This polymorphism lies in an AUUUA motif
of the 3
 
′
 
 UTR of the mRNA of the GR
 
β
 
 isoform and has been shown
to increase mRNA stability and also receptor protein expression.
 
9
 
Derijk 
 
et al
 
. originally detailed the genotype and allele frequencies
of the rs6198 polymorphism in a very small sample size of 30 RA
cases compared with 24 controls and found carriage of the mutant
allele to be associated with signiﬁcant increased risk of RA.
 
8
 
 Here
we report our attempt to replicate and extend these ﬁndings. We have
previously demonstrated strong linkage disequilibrium across the
GR gene locus and suggested haplotype tagging single nucleotide
polymorphisms (SNPs).
 
10
 
 In this current study we looked at three
polymorphisms that in combination capture 95% of all haplotypes
occurring at a frequency of greater than 1% in Caucasians (Fig. 1).
These are an intron B Bcl1 polymorphism, which has been associated
with increased Gc sensitivity and a lower body mass index,
 
11
 
 a ttg
insertion/deletion within intron F (rs2307674) and the SNP lying in
the 3
 
′
 
 untranslated region of exon 9b (rs6198). We studied these
in a well-characterized panel of RA patients and healthy controls
to determine whether polymorphisms of GR contribute to RA
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susceptibility. Utilizing this combination of SNPs allows for the most
comprehensive investigation of GR polymorphisms in RA that has
been carried out to date.
 
Methods
 
Patients and controls
 
Blood samples were obtained with informed written consent. Ethical
approval was obtained from Multicentre Research Ethics Committee
(MREC) (99/8/84) and the University of Manchester committee on
the ethics of research on human beings (8/92/(i)).
All patients and controls were of UK Caucasoid origin.
One hundred and ninety-eight RA cases from the Arthritis
Research Campaign National Repository for families with RA were
studied. Only one affected case per family was selected, at random,
for investigation. All RA cases had disease that met the American
College of Rheumatology 1987 criteria, as modiﬁed for genetic
studies.
DNA was available for 393 control subjects. These were individ-
uals recruited from blood donors and from the records of general
practitioners.
 
Genotyping
 
SNP genotyping was by the dye terminator-based SNaPshot method
(Applied Biosystems, Warrington, UK). In brief, polymerase chain
reactions (10 
 
µ
 
l ﬁnal volume) contained 10 ng of genomic DNA,
0·4 
 
µ
 
l of each primer (25 pmol/
 
µ
 
l), 1 
 
µ
 
l of 10 
 
×
 
 NH
 
4
 
 buffer (Bioline),
1 
 
µ
 
l of dNTPs (Bioline, 2 mM), 0·3 
 
µ
 
l MgCl
 
2
 
 (Bioline, 1·5 mM) and
0·2 
 
µ
 
l of Taq polymerase (Bioline, 5 U/
 
µ
 
l). The primers and probes
used were (5
 
′
 
 to 3
 
′
 
): for the intron B Bcl1 SNP: forward primer CTA
TTC TTC AAA CTG AAT CTT CTG, reverse primer CAA CAC GTA
TAT CTA CAT TTA GAA C, and probe GAC ACC AAT TCC TCT CTT
AAA GAG ATT; for the rs6198 SNP: forward primer AGT GTC TTT
TTA CCT ACG C, reverse primer ATG TTT CTC CAT ATT TGG C, and
probe TGT GGT TTG GTA ATA CCA GAA CAG CAA ATT TAA A.
The presence or absence of a ttg insert (rs2307674) was determined
using capillary electrophoresis for size resolution, relative to a ROX
450 internal size standard, on an ABI Prism 310 DNA Genetic Ana-
lyser (Applied Biosystems), using a ﬂuorescent dye (HEX)-labelled
forward primer. The results were analysed using Genescan analysis
and Genotyper 3·6 software (Applied Biosystems). The rs2307674
forward primer was ACC TCA AGT GAT CCA CCC, and the reverse
primer GTA CAT GGT TAT ACT CAT ATA TAA C.
The RA cases and a proportion of the controls had been previously
genotyped for HLA-DRB1 alleles and shared epitope (SE) status
assigned.
 
Statistical analysis
 
Associations between the GR polymorphisms and RA were analysed
using the 
 
χ
 
2
 
-test (Stata, College Station, TX) and correction for mul-
tiple testing was performed by Bonferroni’s method. Haplotype
analysis was carried out using the expectation-maximization
algorithm implemented in HelixTree (Golden Helix, Bozeman, MT).
Stratiﬁcation analysis was performed to investigate the effects of
gender, disease severity, as assessed by the presence of erosive
disease, age at disease onset (the median age at onset was used as
the cut-off value), and carriage of SE alleles (HLA-DRB1*0401,
*0404, *0101, *0102, *1001 and *1402 were considered positive for
the shared epitope).
The study had > 85% power to detect an odds ratio (OR) of 1·8
or greater with RA susceptibility (
 
P = 
 
0·05).
Fig. 1 Haplotype tagging SNPs. Haplotypes 
(n = 425) occurring with a frequency of > 1% are 
shown. Boldface indicates the haplotypes 
captured by the three haplotype tagging 
polymorphisms (shaded): intron B Bcl1, C → G, 
the presence or absence of the ttg insertion 
(rs2307674) and the rs6198 A → G. (Adapted 
from Stevens et al.
10) 
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Results
 
No deviation from Hardy–Weinberg equilibrium was seen for any
polymorphism in the cases or the controls. Strong linkage disequi-
librium (LD) (
 
r
 
2
 
 = 1) was seen for the polymorphisms studied in
both the case and control groups.
No association with any GR polymorphism was found with
the RA cases when considered as a whole group (Table 1). Sim-
ilarly, no signiﬁcant haplotype associations were seen with RA
susceptibility.
On stratiﬁed analysis, a weak positive association with an excess
of rs6198 AA (wild-type) homozygotes was seen when the SE
negative cases were compared with SE negative controls (Table 2).
Furthermore, use of Bonferroni’s correction for multiple testing
(
 
n
 
 = 3) rendered this observation nonsigniﬁcant (
 
P
 
corr
 
 = 0·15).
No other single or haplotypic association of GR polymorphisms
and no other parameters of RA severity were found.
 
Discussion
 
Inappropriately low endogenous cortisol production may be a con-
tributing factor to the onset and progression of RA. How this arises
has not been ascertained.
 
12
 
 Alternatively, a normal HPA axis response
to inﬂammation may be compromised in RA patients by a reduction
or alteration in GR function. The number of GR
 
α
 
 in lymphocytes
from RA cases was found to be lower than in controls.
 
13
 
 However,
the serum cortisol levels were normal so such apparent downregulation
of receptor expression is difﬁcult to explain. Polymorphism of
the GR gene may inﬂuence GC sensitivity. Certain low-frequency
polymorphisms of GR (ER22/23EK) have been found to be associated
with parameters of Gc sensitivity in normal individuals.
 
14
 
 These
nucleotide changes are in strong LD with the intron B Bcl1
polymorphism in particular, and as such we ﬁnd no evidence of
association of them with RA susceptibility. The possibility of a GR
polymorphism conferring risk for RA was raised by Derijk 
 
et al
 
.
 
8
 
This was of particular interest because the nucleotide change
occurred in the 3
 
′
 
 UTR of the GR
 
β
 
 molecule. If RA cases had an
excessive amount of this variation, which was subsequently found
to have functional signiﬁcance and affect GR
 
β
 
 mRNA stability, then
a possible mechanism for relative GR resistance would have been
Table 1. Frequency of intron B Bcl1, rs2307674 and rs6198 GR SNP 
genotypes in control and RA cases
GR 
polymorphism
Controls n 
(%)
RA cases n 
(%) P-value
Intron B BCl1 (n = 392) (n = 195)
CC 147 (37·5) 76 (39·0)
CG 195 (49·7) 94 (48·2)
GG 50 (12·8) 25 (12·8) 0·81
(n = 384) (n = 191)
rs2307674
ttg/ttg 255 (66·4) 136 (71·2)
ttg/– 119 (31·0) 47 (24·6)
–/– 10 (2·6) 8 (4·2) 0·50
(n = 390) (n = 178)
rs6198
AA 256 (65·6) 129 (72·5)
AG 121 (31·1) 44 (24·7)
GG 13 (3·3) 5 (2·8) 0·13
Table 2. Frequency of intron B BCl1, rs2307674 and rs6198 GR SNP genotypes in controls and in the RA cohort stratiﬁed by erosive disease, age at disease 
onset, and carriage of SE alleles
Genotype Controls
SE status
Erosive disease Age at disease onset SE negative SE positive
Present Absent < 41 years ≥ 42 years Controls RA cases Controls RA cases
Intron B BCl1 (n = 392) (n = 139) (n = 25) (n = 75) (n = 72) (n = 71) (n = 41) (n = 86) (n = 154)
CC 147 (37·5) 58 (41·8) 7 (28·0) 32 (42·7) 31 (43·1) 29 (40·8) 16 (39·1) 29 (33·7) 60 (39·0)
CG 195 (49·7) 63 (45·3) 14 (56·0) 30 (40·0) 28 (38·9) 35 (49·3) 19 (46·3) 47 (54·7) 75 (48·7)
GG 50 (12·8) 18 (12·9) 4 (16·0) 13 (17·3) 13 (18·0) 7 (9·9) 6 (14·6) 10 (11·6) 19 (12·3)
P-value – 0·55 0·37 0·95 0·98 – 0·62 – 0·62
Rs2307674 (n = 384) (n = 135) (n = 25) (n = 73) (n = 72) (n = 71) (n = 41) (n-86) (n = 150)
ttg/ttg 255 (66·4) 101 (74·8) 15 (60·0) 57 (78·1) 31 (43·1) 51 (71·8) 27 (65·9) 56 (65·1) 109 (72·7)
ttg/– 119 (31·0) 31 (23·0) 7 (28·0) 10 (13·7) 28 (38·9) 20 (28·2) 11 (26·8) 26 (30·2) 36 (24·0)
–/– 10 (2·6) 3 (2·2) 3 (12·0) 6 (8·2) 13 (18·0) 0 (0·0) 3 (7·3) 4 (4·7) 5 (3·3)
P-value – 0·10 0·16 0·38 0·38 – 0·20 – 0·22
rs6198 (n = 390) (n = 123) (n = 23) (n = 66) (n = 63) (n = 70) (n = 37) (n = 87) (n = 141)
AA 256 (65·6) 87 (70·7) 19 (82·6) 45 (68·2) 41 (65·0) 44 (62·9) 30 (81·1) 56 (64·4) 99 (70·2)
AG 121 (31·1) 31 (25·2) 4 (17·4) 18 (27·3) 19 (30·2) 22 (31·4) 6 (16·2) 27 (31·0) 38 (27·0)
GG 13 (3·3) 5 (4·1) 0 (0·0) 3 (4·5) 3 (4·8) 4 (5·7) 1 (2·7) 4 (4·6) 4 (2·8)
P-value – 0·44 0·08 0·86 0·79 – 0·05 – 0·30 
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found. Our study aimed to look for variation in GR polymorphism
with RA susceptibility. We speciﬁcally genotyped for the rs6198 SNP
within the 3
 
′
 
 UTR of GR
 
β
 
, in combination with two other changes,
which gave excellent genetic coverage across the GR gene locus.
We have accounted for 95% of all haplotypes across the GR gene by
using this approach.
No evidence for genetic association with GR polymorphisms
and RA susceptibility was observed. This is in agreement with the
ﬁndings of a Korean study of RA, in which the 149 RA cases and
controls were compared and no association with the intron B Bcl1
polymorphism was found with the RA group as a whole, or on
stratiﬁcation for disease severity.
 
15
 
 Although less well powered to
look at, we have also stratiﬁed our patient cohort by parameters of
disease severity. An excess of rs6198 AA (wild-type) homozygotes
was seen when the SE negative cases were compared with the SE
negative controls (Table 2). However, given the relatively small
numbers involved, and the borderline level of signiﬁcance, which is
not maintained once correction for multiple testing is applied, this
ﬁnding needs to be interpreted with caution.
In summary, we have looked at three changes across the GR gene
that capture 95% of all commonly occurring haplotypes, but ﬁnd
no evidence for GR polymorphisms contributing a substantial
genetic effect, either as single point or as haplotypic associations, to
risk of RA. We conclude that GR polymorphisms do not confer
signiﬁcant risk of RA.
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